Keep the Veyvora retatrutide pen refrigerated between 2–8°C at all times when not in use. Do not freeze. Before each injection, remove the pen from the refrigerator and allow it to reach room temperature naturally for approximately 15–30 minutes. Injecting cold peptide solution can increase injection-site discomfort. Check the expiry date and batch number against the included Certificate of Analysis before first use.

Wash hands thoroughly. Remove the pen cap and attach a new, sterile pen needle by screwing it onto the pen tip until secure. Remove both the outer and inner needle caps. To prime, dial a small test dose as indicated in the pen instructions and press the injection button with the needle pointing upward until a drop of solution appears at the needle tip. Priming confirms the pen mechanism is functioning correctly and removes air from the cartridge. Never reuse needles between injections.

Dial the dose selector to the prescribed amount. In Phase 2 clinical trials published in The New England Journal of Medicine (Jastreboff et al., 2023), retatrutide was administered once weekly via subcutaneous injection. Recommended injection sites include the abdomen (at least 5 cm from the navel), the front of the thigh, or the back of the upper arm. Rotate injection sites each week to reduce the risk of lipodystrophy. Pinch the skin at the chosen site, insert the needle at a 90-degree angle, press the injection button fully, and hold for 5–10 seconds before withdrawing.

After injection, carefully replace the outer needle cap using a one-handed scoop technique to avoid needlestick injury. Unscrew and dispose of the used needle in an approved sharps container. Do not discard needles in household waste. Replace the pen cap and return the pen to refrigerated storage immediately. Record the injection date, dose, and site in a personal log to support consistent weekly administration and site rotation tracking. Each Veyvora pen includes batch documentation for your records.